Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity

被引:6
|
作者
Bermudo, Guadalupe [1 ]
Suarez-Cuartin, Guillermo [1 ]
Rivera-Ortega, Pilar [1 ,2 ]
Rodriguez-Portal, Jose Antonio [3 ]
Sauleda, Jaume [4 ]
Nunez, Belen [4 ]
Castillo, Diego [5 ]
Aburto, Myriam [6 ]
Portillo, Karina [7 ]
Balcells, Eva [8 ,9 ,10 ]
Badenes-Bonet, Diana [8 ,9 ,10 ]
Valenzuela, Claudia [11 ]
Fernandez-Fabrellas, Estrella [12 ]
Gonzalez-Budino, Teresa [13 ]
Cano, Esteban [14 ]
Acosta, Orlando [15 ]
Leiro-Fernandez, Virginia [16 ]
Romero, Ana [17 ]
Planas-Cerezales, Lurdes [1 ,18 ]
Villar, Ana [19 ]
Moreno, Amalia [20 ]
Laporta, Rosalia [21 ]
Vicens-Zygmunt, Vanesa [1 ]
Shull, Jessica [1 ]
Franquet, Tomas [5 ]
Luburich, Patricio [22 ]
Molina-Molina, Maria [1 ,10 ]
机构
[1] Univ Barcelona, Univ Hosp Bellvitge, IDIBELL, ILD Unit,Resp Dept, Barcelona, Spain
[2] Manchester Univ NHS Fdn Trust, Wythenshawe Hosp, Resp Dept, ILD Unit, Manchester, Lancs, England
[3] Univ Hosp Virgen del Rocio, Resp Dept, Seville, Spain
[4] Univ Hosp Son Espases, Resp Dept, Mallorca, Spain
[5] Univ Hosp Santa Creu & St Pau, Resp Dept, Barcelona, Spain
[6] Hosp Galdakao, Resp Dept, Bizkaia, Spain
[7] Univ Hosp Germans Trias & Pujol, Resp Dept, Badalona, Spain
[8] Univ Hosp del Mar, Resp Dept, Barcelona, Spain
[9] Pompeu Fabra Univ UPF, Barcelona, Spain
[10] CIBER Enfermedades Resp CIBERES, Madrid, Spain
[11] Univ Hosp Princesa, Resp Dept, Madrid, Spain
[12] Univ Hosp Gen Valencia, Resp Dept, Valencia, Spain
[13] Univ Hosp Cent Asturias HUCA, Resp Dept, Oviedo, Spain
[14] Univ Hosp Lucus Agusti, Resp Dept, Lugo, Spain
[15] Univ Hosp Canarias, Resp Dept, Santa Cruz De Tenerife, Spain
[16] Univ Hosp Alvaro Cunqueiro, Resp Dept, Vigo, Spain
[17] Univ Hosp Virgen de las Nieves, Resp Dept, Granada, Spain
[18] Hosp Viladecans, Resp Dept, Barcelona, Spain
[19] Univ Hosp Vall dHebron, Resp Dept, Barcelona, Spain
[20] Univ Hosp Parc Tauli, Resp Dept, Sabadell, Spain
[21] Univ Hosp Puerta del Hierro, Resp Dept, Majadahonda, Spain
[22] Univ Hosp Bellvitge, ILD Unit, Radiol Dept, Barcelona, Spain
来源
ARCHIVOS DE BRONCONEUMOLOGIA | 2022年 / 58卷 / 02期
关键词
Diffuse interstitial lung disease; Idiopathic pulmonary fibrosis; Early diagnosis; Prognosis; Mortality; INTERSTITIAL LUNG ABNORMALITIES; EFFICACY; INDEX; RISK;
D O I
10.1016/j.arbres.2021.03.018
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction: Idiopathic pulmonary fibrosis (IPF) is progressive and irreversible. Some discrepancies about IPF staging exists, especially in mild phases. Forced vital capacity (FVC) higher than 80% has been considered early or mild IPF even for the design of clinical trials. Methods: Spanish multicentre, observational, retrospective study of IPF patients diagnosed between 2012 and 2016, based on the ATS/ERS criteria, which presented FVC greater or equal 80% at diagnosis. Clinical and demographic characteristics, lung function, radiological pattern, treatment, and follow-up were analyzed. Results: 225 IPF patients were included, 72.9% were men. The mean age was 69.5 years. The predominant high-resolution computed tomography (HRCT) pattern was consistent usual interstitial pneumonia (UIP) (51.6%). 84.7% of patients presented respiratory symptoms (exertional dyspnea and/or cough) and 33.33% showed oxygen desaturation below 90% in the 6 min walking test (6MWT). Anti-fibrotic treatment was initiated at diagnosis in 55.11% of patients. Median FVC was 89.6% (IQR 17) and 58.7% of patients had a decrease of diffusion lung capacity for carbon monoxide (DLCO) below 60% of theoretical value; most of them presented functional progression (61.4%) and higher mortality at 3 years (20.45%). A statistically significant correlation with the 3-years mortality was observed between DLCO <60% and consistent UIP radiological pattern. Conclusions: Patients with preserved FVC but presenting UIP radiological pattern and moderate-severe DLCO decrease at diagnosis associate an increased risk of progression, death or lung transplantation. Therefore, in these cases, preserved FVC would not be representative of early or mild IPF. (C) 2021 SEPAR. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:135 / 141
页数:7
相关论文
共 50 条
  • [1] Reference values for forced vital capacity in idiopathic pulmonary fibrosis
    Pereira, Carlos A. C.
    RESPIRATORY MEDICINE, 2017, 125 : 102 - 102
  • [2] Forced vital capacity, total lung capacity and diffusion capacity in idiopathic pulmonary fibrosis
    Pesonen, Ida
    Gao, Jing
    Kalafatis, Dimitrios
    Carlson, Lisa
    Myllarniemi, Marjukka
    Ferrara, Giovanni
    Skold, Magnus
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [3] Position Paper: Significance of the Forced Vital Capacity in Idiopathic Pulmonary Fibrosis
    Behr, J.
    Bonella, F.
    Bonnet, R.
    Glaeser, S.
    Grohe, C.
    Guenther, A.
    Koschel, D.
    Kreuter, M.
    Kirsten, D.
    Kroegel, C.
    Markart, P.
    Mueller-Quernheim, J.
    Neurohr, C.
    Pfeifer, M.
    Prasse, A.
    Schoenfeld, N.
    Schreiber, J.
    Wirtz, H.
    Witt, C.
    Costabel, U.
    PNEUMOLOGIE, 2015, 69 (08): : 455 - 458
  • [4] The Effect Of Bronchodilators On Forced Vital Capacity In Patients With Idiopathic Pulmonary Fibrosis
    Assayag, D.
    Vittinghoff, E.
    Ryerson, C. J.
    Cocconcelli, E.
    Tonelli, R.
    Elicker, B.
    Golden, J.
    Jones, K. D.
    King, T. E.
    Koth, L. L.
    Lee, J. S.
    Ley, B.
    Wolters, P. J.
    Collard, H. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [5] Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
    Santermans, Eva
    Ford, Paul
    Kreuter, Michael
    Verbruggen, Nadia
    Meyvisch, Paul
    Wuyts, Wim A.
    Brown, Kevin K.
    Lederer, David J.
    Byrne, Adam J.
    Molyneaux, Philip L.
    Sivananthan, Arunon
    Moor, Catharina C.
    Maher, Toby M.
    Wijsenbeek, Marlies
    ADVANCES IN THERAPY, 2019, 36 (11) : 3059 - 3070
  • [6] Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis
    Flaherty, Kevin R.
    Kolb, Martin
    Vancheri, Carlo
    Tang, Wenbo
    Conoscenti, Craig S.
    Richeldi, Luca
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (02)
  • [7] Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
    Eva Santermans
    Paul Ford
    Michael Kreuter
    Nadia Verbruggen
    Paul Meyvisch
    Wim A. Wuyts
    Kevin K. Brown
    David J. Lederer
    Adam J. Byrne
    Philip L. Molyneaux
    Arunon Sivananthan
    Catharina C. Moor
    Toby M. Maher
    Marlies Wijsenbeek
    Advances in Therapy, 2019, 36 : 3059 - 3070
  • [8] Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
    Richeldi, Luca
    Ryerson, Christopher J.
    Lee, Joyce S.
    Wolters, Paul J.
    Koth, Laura L.
    Ley, Brett
    Elicker, Brett M.
    Jones, Kirk D.
    King, Talmadge E., Jr.
    Ryu, Jay H.
    Collard, Harold R.
    THORAX, 2012, 67 (05) : 407 - 411
  • [9] Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity?
    Rodriguez Moncalvo, Juan Jose
    Malet Ruiz, Jose
    Mastroianni, Marcelo
    Khoury, Marina
    Caro, Fabian
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [10] The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis
    Assayag, Deborah
    Vittinghoff, Eric
    Ryerson, Christopher J.
    Cocconcelli, Elisabetta
    Tonelli, Roberto
    Hu, Xiaowen
    Elicker, Brett M.
    Golden, Jeffrey A.
    Jones, Kirk D.
    King, Talmadge E., Jr.
    Koth, Laura L.
    Lee, Joyce S.
    Ley, Brett
    Shum, Anthony K.
    Wolters, Paul J.
    Ryu, Jay H.
    Collard, Harold R.
    RESPIRATORY MEDICINE, 2015, 109 (08) : 1058 - 1062